PharmaBiome is pioneering the development of next-generation microbiome therapies. Our indication-specific bacterial consortia target functional disbalances of the microbiome, delivering solutions for patients with currently incurable chronic diseases starting with ulcerative colitis.
Products, services, technology
Our unique discovery pipeline allows the isolation, cultivation and characterization of previously uncultured, anaerobic intestinal bacteria. Combined with our disruptive and proprietary mixed-culture technology we provide control over production, storage and efficacy of microbiome therapeutics.
We are looking for industrial partnerships to develop our preclinical bacterial consortium in the field of inflammatory bowel diseases and are interested in collaboration to develop further compounds or explore functionality in the intestine.